Peer-influenced content. Sources you trust. No registration required. This is HCN.
News Medical
A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.
Gastroenterology July 13th 2026
MDLinx
Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.
Hematology/Oncology May 12th 2026
Cancer Therapy Advisor
“Patients with stage IB-IIIA or IIB disease should be considered for neoadjuvant and/or adjuvant systemic therapy based on biomarker testing for PD-L1 status, EGFR mutations, and ALK gene fusions.” — NCCN NSCLC Guidelines, Version 3, 2026
Oncology, Medical February 17th 2026
Hematology Advisor
Final analysis confirms venetoclax plus modified intensive chemotherapy achieves durable remissions with 17.9-month treatment-free intervals in fit elderly AML patients, particularly those with de novo disease.
Clinical Pharmacology July 22nd 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS